Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes

Journal of Hypertension

Volumn 34, Issue 2, 2016, Pages 359-367

  Redon, Josep ^a,b   Pichler, Gernot ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Amlodipine; Antihypertensive agents; Blood pressure; Diabetes mellitus; Olmesartan; Perindopril

Indexed keywords

AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS PERINDOPRIL; AMLODIPINE; AMLODIPINE, PERINDOPRIL DRUG COMBINATION; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION; IMIDAZOLE DERIVATIVE; OLMESARTAN; PERINDOPRIL; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; BLOOD PRESSURE; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; HYPERTENSION; MEDICATION COMPLIANCE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PERINDOPRIL; TETRAZOLES; TREATMENT OUTCOME;

EID: 84957563456     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000793     Document Type: Article

References (36)

1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
2. Kjeldsen SE, Messerli FH, Chiang CE, Meredith PA, Liu L. Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin 2012; 28:1685-1697.
3. Kreutz R. Olmesartan/amlodipine: A review of its use in the management of hypertension. Vasc Health Risk Manag 2011; 7:183-192.
4. Ferri C, Croce G, Desideri G. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Adv Ther 2008; 25:300-320.
5. Aksnes TA, Skarn SN, Kjeldsen SE. Treatment of hypertension in diabetes: what is the best therapeutic option? Expert Rev Cardiovasc Ther 2012; 10:727-734.
6. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ 2011; 14:576-583.
7. Degli Esposti L, Saragoni S, Buda S, Degli Esposti E. Drug adherence to olmesartan/amlodipine fixed combination in an Italian clinical practice setting. Clinicoecon Outcomes Res 2014; 6:209-216.
8. Jackson KC, Sheng X, Nelson RE, Keskinaslan A, Brixner DI. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther 2008; 30:1558-1563.
9. Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007; 25:1327-1336.
10. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30:587-604.
11. Scott LJ, McCormack PL. Olmesartan medoxomil: A review of its use in the management of hypertension. Drugs 2008; 68:1239-1272.
12. Volpe M, de la Sierra A, Kreutz R, Laurent S, Manolis AJ. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiovasc Prev 2014; 21:137-147.
13. Zhang Y, Ly C, Yannoutsos A, Agnoletti D, Mourad JJ, Safar ME, et al. Effect of a fixed combination of perindopril and amlodipine on blood pressure control in 6256 patients with not-at-goal hypertension: The AVANT'AGE study. J Am Soc Hypertens 2013; 7:163-169.
14. Ogilvie RI, Anand S, Roy P, De Souza S, PEACH investigators. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study. Clin Drug Investig 2008; 28:673-686.
15. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366:895-906.
16. Hermida RC, Ayala DE, Khder Y, Calvo C. Ambulatory blood pressurelowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: A prospective, randomized, open-label, blinded end-point trial. Clin Ther 2008; 30:108-120.
17. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: A placebo-controlled, forced titration study. Candesartan/ Losartan study investigators. Am J Hypertens 1999; 12:1181-1187.
18. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17:347-353.
19. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783.
20. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
21. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. Vasc Health Risk Manag 2008; 4:653-664.
22. Punzi H, Shojaee A, Waverczak WF, Maa J-F. Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. J Clin Hypertens Greenwich Conn 2011; 13:422-430.
23. Nesbitt SD, Shojaee A, Maa JF, Weir MR. Efficacy of an amlodipine/ olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). J Hum Hypertens 2013; 27:445-452.
24. Lin TH, Tsai CD, Pan JP, Hou CJY, Hsia CH, Tsai JP, et al. Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. Kaohsiung J Med Sci 2013; 29:265-270.
25. Schmieder RE, Böhm M. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens 2011; 25:354-363.
26. Sanford M, Keam SJ. Olmesartan medoxomil/amlodipine. Drugs 2009; 69:717-729.
27. Elliott WJ, Whitmore J, Feldstein JD, Bakris GL. Efficacy and safety of perindopril arginine+amlodipine in hypertension. J Am Soc Hypertens 2015; 9:266-274.
28. Derosa G, Cicero AFG, Carbone A, Querci F, Fogari E, D'Angelo A, et al. Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. Expert Opin Drug Saf 2013; 12:621-629.
29. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303:2043-2050.
30. Manfredini R, Boari B, Smolensky MH, Salmi R, la Cecilia O, Maria Malagoni A, et al. Circadian variation in stroke onset: identical temporal pattern in ischemic and hemorrhagic events. Chronobiol Int 2005; 22:417-453.
31. Cohen MC, Rohtla KM, Lavery CE, Muller JE, Mittleman MA. Metaanalysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am J Cardiol 1997; 79:1512-1516.
32. Tan KW, Leenen FH. Persistence of anti-hypertensive effect after missed dose of perindopril. Br J Clin Pharmacol 1999; 48:628-630.
33. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24:93-103.
34. Ongtengco I, Morales D, Sanderson J, Lu Z-R, Beilin LJ, Burke V, et al. Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two 'missed doses': A randomised, doubleblind comparative trial in Asian patients. J Hum Hypertens 2002; 16:805-813.
35. Myers MG, Leenen FHH, General Practice Research Group. The impact of one or two missed doses on the duration of action of combined perindopril and indapamide. J Hum Hypertens 2007; 21:86-93.
36. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363:2022-2031.